- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe asthma
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1299KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 171KB)
Fluticasone furoate with umeclidinium and vilanterol – November 2021
Fluticasone furoate with umeclidinium and vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses; Trelegy Ellipta 200/62.5/25®
Last updated
4 March 2022
